Trial Profile
DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Jul 2023
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary) ; Varlilumab (Primary) ; Dendritic cells; Diphtheria-tetanus vaccine
- Indications Glioblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms DERIVe
- 17 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 01 Mar 2023 Status changed from suspended to recruiting.
- 14 Dec 2022 Status changed from recruiting to suspended.